drugset / Trial / NCT02241031
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
Phase 2/3
Unknown
250 enrolled
Nanfang Hospital, Southern Medical University
Academy Military Medical Science, China · collabGuangdong Provincial People's Hospital · collabGuangzhou First People's Hospital · collabGuangzhou General Hospital of Guangzhou Military Command · collabHuazhong University of Science and Technology · collabPeking University People's Hospital · collabSouthern Medical University, China · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabSun Yat-sen University · collabThird Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of ex vivo generated megakaryocytic progenitor cells (MPs) in prophylaxis and treatment of thrombocytopenia caused by chemotherapy in patients with acute leukemia (AL).
Timeline
- Start
- 2014-09
- Primary completion
- 2016-09
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interleukin-11 | Protein / enzyme biologic | — | — |
| Subject | megakaryocytic progenitor cells | Cell therapy | — | Intravenous |
| Comparator | recombinant human thrombopoietin | Protein / enzyme biologic | — | — |